(Q43038357)

12 November 2017

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1 reference

1 reference

Mitchell L Shiffman

1

1 reference

12 November 2017

Jennifer Salvatore

2

1 reference

12 November 2017

Sarah Hubbard

3

1 reference

12 November 2017

Angie Price

4

1 reference

12 November 2017

Richard K Sterling

5

1 reference

12 November 2017

R Todd Stravitz

6

1 reference

12 November 2017

Velimir A Luketic

7

1 reference

12 November 2017

Arun J Sanyal

8

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

12 November 2017

1 reference

12 November 2017

46

1 reference

12 November 2017

371-379

1 reference

12 November 2017

2

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

12 November 2017

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

7 January 2021

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

7 January 2021

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

1 reference

7 January 2021

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

1 reference

7 January 2021

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin

1 reference

7 January 2021

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

7 January 2021

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

7 January 2021

Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis

1 reference

7 January 2021

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

1 reference

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

7 January 2021

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature

1 reference

7 January 2021

Erythropoietin-induced, antibody-mediated pure red cell aplasia

1 reference

7 January 2021

Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.

1 reference

7 January 2021

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy

1 reference

7 January 2021

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

7 January 2021

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

7 January 2021

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

1 reference

7 January 2021

New kinetic models for the hepatitis C virus

1 reference

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

1 reference

7 January 2021

Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.

1 reference

7 January 2021

Controversies in the management of hepatitis C virus infection after liver transplantation.

1 reference

7 January 2021

Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients

1 reference

7 January 2021

Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21712

1 reference

12 November 2017

1 reference